Mutation Combinations Database

Comprehensive guide to genetic mutation combinations in colorectal cancer, their clinical implications, and treatment recommendations.

64
Total Combinations
39
Actionable Targets
14
Categories
Showing 64 combinations
BRAF Non-V600
Intermediate
BRAF
2.00% prevalence

Different biology. May retain anti-EGFR sensitivity.

Recommended
Standard chemotherapy Anti-EGFR possible
Avoid
Encorafenib
BRAF Pathway
Level 3
FGFR Alterations
Intermediate
FGFR1 FGFR2 FGFR3
2.00% prevalence

FGFR inhibitors approved in other tumors. CRC trials ongoing.

Recommended
Clinical trials Standard therapy
Rare Fusions
Level 3
STK11/LKB1 Loss
Intermediate
STK11
2.00% prevalence

May cause immunotherapy resistance. Watch for CRC data.

Recommended
Standard therapy Metabolic targeting trials
Emerging Targets
Level 3
MET Amplification
Poor
MET
1.50% prevalence

Associated with poor prognosis and anti-EGFR resistance.

Recommended
Clinical trials Standard therapy
Avoid
Anti-EGFR if amplified
Rare Fusions
Level 3
About This Database

This database contains clinically relevant mutation combinations in colorectal cancer. Each combination includes:

  • Genes involved - The genetic alterations present
  • Prognosis - Expected outcome classification
  • Prevalence - How common in CRC patients
  • Recommended treatments - Evidence-based options
  • Treatments to avoid - Known ineffective therapies
  • Evidence level - Strength of supporting data

Actionable combinations have FDA-approved targeted therapies or strong clinical trial evidence. Always consult with your oncologist for personalized treatment decisions.